Hormonal therapies, including selective estrogen receptor modulators (SERMs) such as tamoxifen, aromatase inhibitors such as letrozole and anastrozole, and selective estrogen receptor degraders (SERDs) such as fulvestrant, have proven to be highly effective in treating ER‐positive breast cancer [21]. Here, ESR1 is linked to breast carcinoma.